What is Biodapt?
Biodapt operates at the intersection of orthopedic engineering and high-performance athletics. The company specializes in the design, manufacturing, and distribution of advanced lower limb prosthetic components, such as the MOTO KNEE 2, which are engineered to withstand the rigorous demands of action sports. By bridging the gap between clinical prosthetic utility and extreme athletic performance, Biodapt serves a diverse demographic ranging from elite adaptive competitors to active individuals seeking greater mobility. Their market position is defined by a commitment to durability and versatility, ensuring that amputees can engage in high-impact activities with confidence and precision.
How much funding has Biodapt raised?
Biodapt has raised a total of $15K across 1 funding round:
Debt
$15K
Debt (2021): $15K with participation from PPP
Key Investors in Biodapt
PPP
Public-Private Partnership
What's next for Biodapt?
With the infusion of $15K, Biodapt is well-positioned to accelerate its product development roadmap and expand its market reach. The current Series A/B growth stage suggests a strategic pivot toward scaling manufacturing capabilities and enhancing distribution networks to support a broader international footprint. Future initiatives will likely focus on refining existing prosthetic technologies and exploring new materials to further improve the user experience for adaptive athletes. As the company matures, the focus will remain on maintaining its competitive edge through continuous innovation in the prosthetic space, potentially attracting further institutional backing to solidify its leadership in the adaptive sports technology market.
See full Biodapt company page
